Frontiers in oral health · 2025
Irisin, a promising adipomyokine, shows low levels in relation to periodontal diseases, unlike visfatin and IL-6 (case-control study).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salim Farah Sabah, Saliem Saif S
Аннотация
INTRODUCTION: Adipose tissue releases pro- and anti-inflammatory cytokines and hormones such as irisin, visfatin, and interleukin-6, which may be linked to periodontal diseases.
OBJECTIVES: Our study aimed to determine salivary irisin, visfatin, and interleukin-6 levels in gingivitis and periodontitis patients, compare them with healthy periodontal patients, and evaluate the association between these biomarkers.
MATERIALS AND METHODS: Ninety participants were involved in this case-control study: 30 patients diagnosed with periodontitis (P), 30 patients with gingivitis (G), and 30 periodontally healthy subjects (control; C). The periodontal clinical parameters were documented. The ELISA test examined irisin, visfatin, and interleukin-6 saliva levels. Data were analyzed using SPSS (V.29).
RESULTS: Irisin significantly decreased in gingivitis and periodontitis compared to the control group (p < 0.05). In contrast, gingivitis and periodontitis reported elevated levels of visfatin and interleukin-6 compared to the control group (p < 0.05). Visfatin levels did not significantly change between gingivitis and periodontitis (p > 0.05). All periodontal clinical measures showed a significant negative association with irisin (p < 0.05), except plaque index in the gingivitis group. At the same time, visfatin and interleukin-6 showed significant positive relationships with all clinical periodontal markers (p < 0.05).
CONCLUSIONS: Salivary irisin levels were reduced in individuals with gingivitis and periodontitis, whereas visfatin and interleukin-6 levels were elevated. These biomarkers may predict susceptibility to periodontal disease.
OBJECTIVES: Our study aimed to determine salivary irisin, visfatin, and interleukin-6 levels in gingivitis and periodontitis patients, compare them with healthy periodontal patients, and evaluate the association between these biomarkers.
MATERIALS AND METHODS: Ninety participants were involved in this case-control study: 30 patients diagnosed with periodontitis (P), 30 patients with gingivitis (G), and 30 periodontally healthy subjects (control; C). The periodontal clinical parameters were documented. The ELISA test examined irisin, visfatin, and interleukin-6 saliva levels. Data were analyzed using SPSS (V.29).
RESULTS: Irisin significantly decreased in gingivitis and periodontitis compared to the control group (p < 0.05). In contrast, gingivitis and periodontitis reported elevated levels of visfatin and interleukin-6 compared to the control group (p < 0.05). Visfatin levels did not significantly change between gingivitis and periodontitis (p > 0.05). All periodontal clinical measures showed a significant negative association with irisin (p < 0.05), except plaque index in the gingivitis group. At the same time, visfatin and interleukin-6 showed significant positive relationships with all clinical periodontal markers (p < 0.05).
CONCLUSIONS: Salivary irisin levels were reduced in individuals with gingivitis and periodontitis, whereas visfatin and interleukin-6 levels were elevated. These biomarkers may predict susceptibility to periodontal disease.